Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Table 5. General guidelines for PegIFN-RBV dose reduction or discontinuation

for Health Care Providers

Table 5. General guidelines for PegIFN-RBV dose reduction or discontinuation (32,33,57,58)

Back to Tables

PegIFN dose recommendationa

ANC, absolute neutrophil count; BOC, boceprevir; GCSF, granulocyte colony-stimulating factor; Hb, hemoglobin; HCV, hepatitis C virus; PegIFN, peginterferon; RBV, ribavirin; TVR, telaprevir; WBC, white blood cell counts.

a Manufacturer package insert recommendations.

b If dose is maintained outside of manufacturer recommendations, monitor ANC more frequently, and counsel patient on neutropenic precautions. In post-liver transplantation or HIV/HCV-coinfected patients who remain neutropenic despite dose reduction, consider starting GCSF until resolution.

c If dose is maintained outside of manufacturer recommendations, monitor platelet counts, and signs or symptoms of unusual bleeding or bruising more frequently.

WBC
<1.5 x 109/l PegIFN alfa-2b: reduce dose to 1 mcg/kg per week,
then to 0.5 mcg/kg per week if needed
<1.0 x 109/l Discontinue PegIFN alfa-2b until resolution
ANCb
<0.75 x 109/lPegIFN alfa-2a: reduce dose to 135 mcg per week
PegIFN alfa-2b: reduce dose to 1 mcg/kg per week,
then to 0.5 mcg/kg per week if needed
<0.50 x 109/l Discontinue PegIFN until resolution
Plateletsc
<50 k/mm3PegIFN alfa-2a: reduce dose to 90 mcg per week
PegIFN alfa-2b: reduce dose to 1 mcg/kg per week,
then to 0.5 mcg/kg per week if needed
<25 k/mm3Discontinue PegIFN until resolution
RBV dose recommendation
Hb
<11.0, but >10 g/dl No change in RBV dose if patient has minimal symptoms
In a symptomatic patient, consider RBV dose reduction
<10.0, but >8.5 g/dl Decrease RBV, consider starting an erythropoietic growth factor
In patients with a cardiac history, reduce RBV dose and reduce PegIFN alfa-2b dose by 50%
<8.5 g/dl Discontinue RBV until resolution
If RBV is stopped for ≥ 7 days or discontinued in patients who are concomitantly receiving BOC or TVR, then BOC or TVR must be permanently discontinued